News | December 29, 2022
AIIMS organises consultation on ‘C2IQ’
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Positive opinions based on significant survival benefit
The current ruling will assure the safety of the use of Ranitidine for Indian patients
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
It will undertake academic and collaborative research activities in Ayurveda, including herbal medicine and yoga, as well as design academic standards, short-term/medium-term courses, and educational guidelines
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
Subscribe To Our Newsletter & Stay Updated
